Peer-influenced content. Sources you trust. No registration required. This is HCN.
MedPage Today
Giant cell arteritis (GCA) is one of the most dangerous rheumatologic conditions, and mortality rates among patients with the condition in Canada’s Ontario province has researchers very concerned without any explanation for the recent increases in mortality they documented. MedPage Today shares the report from Arthritis Care & Research.
Rheumatology June 29th 2022
Annals of Internal Medicine
Primary hyperparathyroidism (PHPT) is associated with increased risk for fractures, cardiovascular disease, kidney disease, and cancer, along with increased mortality. In mild PHPT with modest hypercalcemia and without known morbidities, parathyroidectomy is debated because no long-term randomized trials have been performed related to it.
Cardiology April 27th 2022
Medical Professionals Reference (MPR)
Can you solve the case? A 40-year-old man presents with intermittent burning on his feet over the past three years, typically in colder months, often after outdoor activities. He has no history of disease, denies drug use, and does not smoke. What’s your diagnosis?
Allergy & Immunology February 23rd 2022
Similarly, can you determine how to treat a 22-year-old man with Marfan syndrome who complains of an asymptomatic rash on his arms and neck that began over a year ago? Take the quiz to test your diagnostic prowess.
Allergy & Immunology February 15th 2022
JAMA Network
A new cohort study has found physical, mental, and cognitive symptoms in patients one year after being treated in an intensive care unit (ICU) for COVID-19. The study involved an exploratory multicenter prospective cohort study that included 246 patients who were alive one year following ICU treatment for COVID-19. Three-quarters of patients reported physical symptoms, 1/4 reported mental symptoms, and about 15% reported cognitive symptoms a year after being hospitalized with the respiratory illness.
Cardiology February 8th 2022
In contradistinction to recent reports that showed increased risk of death and no clinical benefit with escalation of allopurinol for progressive CKD, this 5-year population-based review found no increased mortality risk in escalating allopurinol dose and achieving target serum urate levels.
Family Medicine/General Practice February 1st 2022